The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia

Max J Gordon, Alexey V Danilov, Max J Gordon, Alexey V Danilov

Abstract

Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relapsed/refractory setting and over chlorambucil in older patients with de novo disease. The phase III ECOG-ACRIN trial extended these results to young, fit patients, demonstrating a significant survival advantage to ibrutinib plus rituximab over fludarabine, cyclophosphamide, and rituximab. Similarly, the Alliance trial demonstrated the superiority of ibrutinib over bendamustine with rituximab as frontline in elderly patients. Challenges with ibrutinib include toxicity, development of resistance, and need for indefinite therapy. The second generation BTK inhibitor acalabrutinib may cause less off-target toxicity. The ELEVATE TN trial demonstrated the superiority of acalabrutinib with or without obinutuzumab over chlorambucil and obinutuzumab as frontline therapy for elderly or comorbid patients. Promising early results from the phase II CAPTIVATE and CLARITY trials, which combined ibrutinib with venetoclax, suggest a future role for minimal residual disease (MRD) testing to determine treatment duration. The ongoing phase III GAIA/CLL13, ECOG EA9161, Alliance A041702, CLL17, and [ClinicalTrials.gov identifier: NCT03836261] trials will assess various combinations of ibrutinib/acalabrutinib, venetoclax, and anti-CD20 antibodies. These trials will answer key questions in the treatment of CLL: should novel agents in CLL be used in combination or sequentially? What is the best frontline agent? Can treatment be safely stopped with BTK inhibitors? Can undetectable MRD be used to determine treatment duration? In this review, we will discuss these and other aspects of the evolving role of BTK inhibition in CLL.

Keywords: BTK inhibitor; acalabrutinib; chronic lymphocytic leukemia; combination therapy; ibrutinib; targeted therapy.

Conflict of interest statement

Conflict of interest statement: AVD reports consultancy from Abbvie, Beigene, Celgene, Curis, Janssen, Karyopharm, Nurix, Seattle Genetics, Teva Oncology, and TG Therapeutics; research funding from Aptose Biosciences, Bristol-Myers Squibb, Gilead Sciences, and Takeda Oncology; and consultancy and research funding from AstraZeneca, Bayer Oncology, Genentech, and Verastem Oncology.

© The Author(s), 2021.

References

    1. Hallek M, Cheson BD, Catovsky D, et al.. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745–2760.
    1. Eichhorst B, Fink AM, Bahlo J, et al.. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928–942.
    1. Hallek M, Fischer K, Fingerle-Rowson G, et al.. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
    1. Shanafelt TD, Wang XV, Kay NE, et al.. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019; 381: 432–443.
    1. Smith CI. From identification of the BTK kinase to effective management of leukemia. Oncogene 2017; 36: 2045–2053.
    1. Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012; 31: 119–132.
    1. Stevenson FK, Krysov S, Davies AJ, et al.. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313–4320.
    1. Mohamed AJ, Yu L, Backesjo CM, et al.. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009; 228: 58–73.
    1. Sharma S, Orlowski G, Song W. Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J Immunol 2009; 182: 329–339.
    1. Burger JA, Tedeschi A, Barr PM, et al.. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425–2437.
    1. Byrd JC, Brown JR, O’Brien S, et al.. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.
    1. Danilov AV, Herbaux C, Walter HS, et al.. Phase Ib Study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia. Clin Cancer Res 2020; 26: 2810–2818.
    1. Ghia P, Pluta A, Wach M, et al.. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2020; 38: 2849–2861.
    1. Tam CS, Trotman J, Opat S, et al.. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 2019; 134: 851–859.
    1. Danilov AV, Persky DO. Incorporating acalabrutinib, a selective next-generation bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. Br J Haematol. Epub ahead of print 20 November 2020. DOI: 10.1111/bjh.17184.
    1. Brown JR, Eichhorst BF, Ghia P, et al.. A phase 3 trial comparing the efficacy and safety of acalabrutinib in combination with venetoclax with or without obinutuzumab, compared with investigator’s choice of chemoimmunotherapy in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 mutation. Blood 2019; 134(Suppl. 1): 4318.
    1. Burger JA, Sivina M, Jain N, et al.. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019; 133: 1011–1019.
    1. Julia VT, Carsten N, Kater AP, et al.. The GAIA (CLL13) trial: an international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). J Clin Oncol 2018; 36(Suppl. 15): TPS7582.
    1. Sharman JP, Egyed M, Jurczak W, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395: 1278–1291.
    1. Tam CS, Siddiqi T, Allan JN, et al.. Ibrutinib (Ibr) plus Venetoclax (Ven) for first-line treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study. Blood 2019; 134(Suppl. 1): 35.
    1. Woyach J, Ruppert AS, Perez G, et al.. Alliance A041702: a randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (⩾ 70 years of age) with Chronic Lymphocytic Leukemia (CLL). Blood 2019; 134(Suppl. 1): 1751.
    1. Woyach JA, Ruppert AS, Heerema NA, et al.. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018; 379: 2517–2528.
    1. Lew TE, Anderson MA, Lin VS, et al.. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv 2020; 4: 165–173.
    1. Thompson PA, Tam CS, O’Brien SM, et al.. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303–309.
    1. Byrd JC, Furman RR, Coutre SE, et al.. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
    1. Byrd JC, Hillmen P, O’Brien S, et al.. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 2019; 133: 2031–2042.
    1. O’Brien S, Jones JA, Coutre SE, et al.. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016; 17: 1409–1418.
    1. Ahn IE, Farooqui MZH, Tian X, et al.. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood 2018; 131: 2357–2366.
    1. Byrd JC, Harrington B, O’Brien S, et al.. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 323–332.
    1. Tam CS, Robak T, Ghia P, et al.. Efficacy and safety of zanubrutinib in patients with treatment-naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): initial results from arm C of the sequoia (BGB-3111-304) trial. Blood 2019; 134(Suppl. 1): 499.
    1. Davids MS, Brander DM, Kim HT, et al.. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol 2019; 6: e419–e428.
    1. Jain N, Thompson PA, Burger JA, et al.. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). J Clin Oncol 2017; 35(Suppl. 15): 7522.
    1. Chanan-Khan A, Cramer P, Demirkan F, et al.. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17: 200–211.
    1. Moreno C, Greil R, Demirkan F, et al.. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 43–56.
    1. Seymour JF, Kipps TJ, Eichhorst B, et al.. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378: 1107–1120.
    1. Fischer K, Al-Sawaf O, Bahlo J, et al.. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019; 380: 2225–2236.
    1. Jain N, Keating M, Thompson P, et al.. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med 2019; 380: 2095–2103.
    1. Hillmen P, Rawstron AC, Brock K, et al.. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol 2019; 37: 2722–2729.
    1. Rogers KA, Huang Y, Ruppert AS, et al.. Phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Blood 2018; 132(Suppl. 1): 693.
    1. Burger JA, Barr PM, Robak T, et al.. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020; 34: 787–798.
    1. Brander DM, Rhodes J, Pagel JM, et al.. Applicability of the Chronic Lymphocytic Leukemia (CLL)-IPI on patients treated with front-line ibrutinib in the real world: the case for new prognostic models. Blood 2017; 130(Suppl. 1): 1719.
    1. Gordon MJ, Sitlinger A, Salous T, et al.. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: results from a multicenter retrospective cohort study. Leuk Res 2020; 89: 106302.
    1. Kittai AS, Lunning M, Danilov AV. Relevance of prognostic factors in the era of targeted therapies in CLL. Curr Hematol Malig Rep 2019; 14: 302–309.
    1. Soumerai JD, Ni A, Darif M, et al.. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol 2019; 6: e366–e374.
    1. Mato AR, Nabhan C, Thompson MC, et al.. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica 2018; 103: 874–879.
    1. Awan FT, Schuh A, Brown JR, et al.. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019; 3: 1553–1562.
    1. Yazdy M, Mato A, Roeker L, et al.. Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real world patients. Blood 2019; 134: 4311.
    1. Woyach JA, Blachly JS, Rogers KA, et al.. Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia. Cancer Discov 2020; 10: 394–405.
    1. Walter HS, Rule SA, Dyer MJS, et al.. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 2016; 127: 411–419.
    1. Gordon MJ, Churnetski M, Alqahtani H, et al.. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer 2018; 124: 3192–3200.
    1. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 2019; 133: 1298–1307.
    1. Xiao L, Salem J-E, Clauss S, et al.. Ibrutinib-mediated atrial fibrillation due to inhibition of CSK. Circulation 2020; 142: 2443–2455.
    1. Brown JR, Moslehi J, O’Brien S, et al.. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 2017; 102: 1796–1805.
    1. Archibald WJ, Rabe KG, Kabat BF, et al.. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. Epub ahead of print 1 June 2020. DOI: 10.1007/s00277-020-04094-3.
    1. Lampson BL, Yu L, Glynn RJ, et al.. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 2017; 129: 2581–2584.
    1. Dickerson T, Wiczer T, Waller A, et al.. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 2019; 134: 1919–1928.
    1. Jaglowski SM, Jones JA, Flynn JM, et al.. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012; 30(Suppl. 15): 6508.
    1. Brown JR, Moslehi J, Ewer MS, et al.. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol 2019; 184: 558–569.
    1. Rigolin GM, Cavallari M, Quaglia FM, et al.. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood 2017; 129: 3495–3498.
    1. Gordon MJ, Kaempf A, Sitlinger A, et al.. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): a novel comorbidity score derived from a large multicenter retrospective cohort study of patients treated with ibrutinib and/or Chemo-Immunotherapy (CIT). Blood 2019; 134(Suppl. 1): 4286.
    1. Gordon MJ, Huang J, Chan RJ, et al.. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. Br J Haematol. Epub ahead of print 29 June 2020. DOI: 10.1111/bjh.16879.
    1. Ahn IE, Underbayev C, Albitar A, et al.. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017; 129: 1469–1479.
    1. Woyach JA, Ruppert AS, Guinn D, et al.. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 2017; 35: 1437–1443.
    1. Chen Q, Jain N, Ayer T, et al.. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol 2017; 35: 166–174.
    1. Shanafelt TD, Borah BJ, Finnes HD, et al.. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract 2015; 11: 252–258.
    1. Flowers CR, Pro B. Racial differences in chronic lymphocytic leukemia. Digging deeper. Cancer 2013; 119: 3593–3595.
    1. Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the hospital clinic of Barcelona: an interim report. Leukemia 2020; 34: 1954–1956.
    1. Koffman B, Mato A, Byrd JC, et al.. Management of CLL patients early in the COVID-19 pandemic: an international survey of CLL experts. Am J Hematol 2020; 95: E199–E203.
    1. Treon SP, Castillo JJ, Skarbnik AP, et al.. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135: 1912–1915.
    1. Mato AR, Roeker LE, Lamanna N, et al.. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020; 136: 1134–1143.
    1. Scarfò L, Chatzikonstantinou T, Rigolin GM, et al.. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia 2020; 34: 2354–2363.
    1. Fraser G, Cramer P, Demirkan F, et al.. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia 2019; 33: 969–980.
    1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603–3613.
    1. Cramer P, Tresckow JV, Robrecht S, et al.. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica. Epub ahead of print 27 February 2020. DOI: 10.3324/haematol.2019.223693.
    1. Michallet A-S, Dilhuydy M-S, Subtil F, et al.. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2019; 6: e470–e479.
    1. Nastoupil LJ, Lunning MA, Vose JM, et al.. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 2019; 6: e100–e109.
    1. Furman RR, Sharman JP, Coutre SE, et al.. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.
    1. Mato AR, Hill BT, Lamanna N, et al.. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2017; 28: 1050–1056.
    1. Jones JA, Mato AR, Wierda WG, et al.. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19: 65–75.
    1. Greil R, Fraser G, Leber B, et al.. Efficacy and safety of Ibrutinib (IBR) after Venetoclax (VEN) treatment in IBR-naïve patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): follow-up of patients from the MURANO study. Blood 2018; 132(Suppl. 1): 5548.
    1. Herman SE, Niemann CU, Farooqui M, et al.. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28: 2188–2196.
    1. Lampson BL, Tyekucheva S, Crombie JL, et al.. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated Chronic Lymphocytic Leukemia (CLL). Blood 2019; 134(Suppl. 1): 32.
    1. Furstenau M, De Silva N, Eichhorst B, et al.. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere 2019; 3: e287.
    1. Heltai S, Ghia P, Scarfo L. Relevance of minimal residual disease in the era of targeted agents. Cancer J 2019; 25: 410–417.
    1. Gauthier J, Hirayama AV, Purushe J, et al.. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 2020; 135: 1650–1660.
    1. Gill SI, Vides V, Frey NV, et al.. Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. Blood 2018; 132(Suppl. 1): 298.
    1. Turtle CJ, Hay KA, Hanafi LA, et al.. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 2017; 35: 3010–3020.
    1. Fraietta JA, Beckwith KA, Patel PR, et al.. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 2016; 127: 1117–1127.
    1. Ruella M, Kenderian SS, Shestova O, et al.. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 2017; 31: 246–248.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe